Oct 16 (Reuters) - Omeros Corp said on Monday it will discontinue a trial studying its therapy to treat a type of kidney disease after it failed to meet the main goal of the late-stage study.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shinjini Ganguli)
There's a much more popular AI stock on Capitol Hill than the leading AI chip maker.
Donald Trump’s aides have drawn up secret plans to oust the chairman of the Federal Reserve and allow the president to set interest rates, according to reports.
The $50 million purchase could turn into Nvidia's biggest investment.
These proven wealth builders could be exactly what you're searching for right now.
The property report includes 85 major metropolitan areas in the U.S. with populations of at least 750,000.
Walmart's CEO went from earning $6.50 an hour to $25 million a year—here are his three tips for climbing the corporate ladder like him
The JPMorgan Nasdaq Equity Premium Income ETF offers a compelling blend of income and upside to my portfolio.
Jamie Dimon and Jerome Powell are taking the European viewpoint on soaring debt levels in the U.S.
Here's what could happen next to Microsoft shares.
There are benefits to investing in stocks that have reasonable multiples and aren't as dependent on future earnings growth to justify their valuations.